Department of Chemistry, School of Natural Sciences, The University of Manchester, Oxford Road, ManchesterM13 9PL, United Kingdom.
Department of Biochemistry, Faculty of Life Sciences, University of Central Punjab, Lahore 54590, Pakistan.
Anticancer Agents Med Chem. 2021 Oct 28;21(16):2181-2191. doi: 10.2174/1871520621666210126092303.
Cancer is one of the leading causes of death in the world affecting millions of people. The commercially available anticancer drugs lack the selectivity and show several undue side effects during the biologically targeted therapy, thus calling for the exploration of wider chemical space to furnish new structural leads with promising anticancer potential. In this endeavor, we synthesized a series of coumarinyl thiazolotriazoles with diverse functional group tolerance and will be tested for their anticancer properties against cancer cell lines (HeLa and MCF-7) and a normal cell line (BHK-21).
To overcome such complications, in the current study, we evaluated the cytotoxic effects of coumarinyl thiazolotriazole hybrids on human breast adenocarcinoma (MCF-7), cervical adenocarcinoma (HeLa) cells and normal cells i.e., Baby Hamster Kidney cells (BHK-21) using MTT (dimethyl-2-thiazolyl- 2,5-diphenyl-2H-tetrazolium bromide) assay. DNA binding studies of compound 6c was performed on Herring- Sperm DNA (HS-DNA) and docking studies were also carried out. The mechanistic studies were performed on potent compounds by fluorescent microscopic studies, release of Lactate Dehydrogenase (LDH) and mitochondrial membrane potential, activation of caspase-9 and -3 and flow cytometric analysis.
As revealed by MTT assay, compounds 6m and 6c were identified as the most potent derivatives among the tested series with IC values of 5.64 and 29.1 μM against HeLa and MCF cells, respectively as compared to cisplatin which gave IC values of 11.3 and 6.20 μM, respectively. DNA binding studies of compound 6c showed the binding of compound in DNA with Gibbs free energy of ‒17 KJ/mol and docking studies validated the DNA binding studies. Fluorescent microscopic studies using 4',6-diamidino-2-phenylindole (DAPI) and Propidium Iodide (PI) staining confirmed the occurrence of apoptosis in HeLa cells treated with the most active compound 6m. Moreover, compounds 6m and 6c also triggered the release of Lactate Dehydrogenase (LDH) in treated HeLa and MCF-7 cells while a luminescence assay displayed a remarkable increase in the activity of caspase-9 and -3. Moreover, flow cytometric results revealed that compound 6m caused G /G arrest in the treated HeLa cells.
Our results suggested that the compound possesses chemotherapeutic properties against breast cancer and cervical adenocarcinoma cells, thus warranting further research to test the anticancer efficacy of this compound at clinical level.
癌症是世界上主要的死亡原因之一,影响着数百万人。市售的抗癌药物缺乏选择性,并在生物靶向治疗中表现出多种不当的副作用,因此需要探索更广泛的化学空间,为具有潜在抗癌作用的新结构提供线索。在这项研究中,我们合成了一系列具有不同官能团耐受性的香豆素噻唑并三唑,并将其测试对癌细胞系(HeLa 和 MCF-7)和正常细胞系(BHK-21)的抗癌特性。
为了克服这些并发症,在本研究中,我们使用 MTT(二甲基噻唑基-2,5-二苯基-2H-四唑溴盐)测定法评估香豆素噻唑并三唑杂合体对人乳腺癌(MCF-7)、宫颈腺癌(HeLa)细胞和正常细胞(BHK-21)的细胞毒性作用。还对化合物 6c 与鲱精 DNA(HS-DNA)的 DNA 结合研究进行了研究,并进行了对接研究。通过荧光显微镜研究、乳酸脱氢酶(LDH)释放和线粒体膜电位、半胱天冬酶-9 和 -3 的激活以及流式细胞术分析对有效化合物进行了机制研究。
MTT 测定表明,化合物 6m 和 6c 是测试系列中最有效的衍生物,对 HeLa 和 MCF 细胞的 IC 值分别为 5.64 和 29.1 μM,而顺铂的 IC 值分别为 11.3 和 6.20 μM。化合物 6c 的 DNA 结合研究表明,化合物与 DNA 的结合具有-17 KJ/mol 的吉布斯自由能,对接研究验证了 DNA 结合研究。使用 4',6-二脒基-2-苯基吲哚(DAPI)和碘化丙啶(PI)染色的荧光显微镜研究证实了用最有效的化合物 6m 处理的 HeLa 细胞中发生了细胞凋亡。此外,化合物 6m 和 6c 还在处理的 HeLa 和 MCF-7 细胞中引发了乳酸脱氢酶(LDH)的释放,而发光测定显示半胱天冬酶-9 和 -3 的活性显著增加。此外,流式细胞术结果表明,化合物 6m 导致处理的 HeLa 细胞中 G / G 期停滞。
我们的结果表明,该化合物对乳腺癌和宫颈腺癌细胞具有化疗特性,因此需要进一步研究以测试该化合物在临床水平上的抗癌功效。